Mankind Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹4,338 Cr +17.3% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
MP

Mankind Pharma Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Mankind Pharma Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹3,570Cr
+24.5% YoY
+15.9% QoQ
Net profit
₹445Cr
−18% YoY
+4.7% QoQ
Margin
24%
+1 pp YoY
+2 pp QoQ
Price₹2,384
Market cap₹1.0L Cr
P/E47.0

The short version

BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2). Profit After Tax (PAT) declined 17.4% YoY in Q1 FY26 due to higher finance and depreciation costs linked to BSV consolidation.

From Mankind Pharma Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2).
  • International business growth for BSV is expected to be upwards of 20%, supported by market penetrations like Russia and newer markets.
  • Domestic BSV growth is driven by both Rx and specialty segments (e.g., fertility drugs with 10-35%+ growth, anti-snake venom with high double-digit growth).
  • Mankind's domestic business organic growth is at 10% year-on-year, with overall company growth (including BSV) at 24.5%.
  • Modern trade and e-commerce channels in the OTC segment grew ~50% YoY, with channel share increasing to 11%.

2 more points from Mankind Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Mankind Pharma is investing in a new biologic/biosimilar facility at Baroda, aimed at scaling up and de-risking operations from their Ambernath site (BSV facility).
  • The Capex for Phase 1 of this biologic facility is estimated around Rs. 150 to Rs. 200 crore, expected to be completed by the end of the next calendar year.
  • Approximately Rs. 100 crore of this Capex is anticipated as cash outflow in FY26.
  • This Capex includes all biologic products of BSV, including Anti-D and Anti-ID.
  • The biologic facility development is planned in two phases: first for drug substance and second for drug products.
  • Mankind is also expanding its biological R&D facilities to strengthen innovation capabilities.

2 more points from Mankind Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant operational and growth updates include: - BSV business expected to grow 18%-20% with increasing traction internationally and in specialty segments. - Ongoing international product registrations and approvals, including recent board approval for Russia. - New biological facility at Ambernath under construction to scale up and de-risk BSV operations, with Capex around Rs. 150-200 crores expected by end of calendar year 2026. - Expansion in R&D and manufacturing capacities to support pipeline and export markets, including Dydrogesterone facility running at ~60% capacity, expected to increase as approvals arrive.

2 more points from Mankind Pharma Ltd's call on order book

Create a free account to keep reading this call

Mankind Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Mankind Pharma Ltd Q1 FY26 results — key figures

Mankind Pharma Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue3,5702,868+24.5%3,079+15.9%
Operating profit (EBITDA)847672+26%683+24%
Operating margin24%23%+1 pp22%+2 pp
Profit before tax540666-18.9%511+5.7%
Net profit (PAT)445543-18%425+4.7%
EPS (₹)10.6213.39-20.7%10.20+4.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.3K Cr, net profit ₹716 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Mankind Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Mankind Pharma Ltd Q1 FY26 results?

BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2). Profit After Tax (PAT) declined 17.4% YoY in Q1 FY26 due to higher finance and depreciation costs linked to BSV consolidation.

What is Mankind Pharma Ltd share price analysis?

Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.

Is Mankind Pharma Ltd planning capital expenditure?

Mankind Pharma is investing in a new biologic/biosimilar facility at Baroda, aimed at scaling up and de-risking operations from their Ambernath site (BSV facility).

Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.